When is it better to eat dhea in vitro and who can't? When is it better to eat dhea in vitro and who can't? sage
When is it better to eat dhea in vitro and who can't?
When doing test tubes, eat them when ovulation is promoted, and don't eat them when transplanting. When is the best time to eat dhea? Dehydroepiandrosterone is more suitable for taking with meals. Of course, you can also take it after meals. If people take this health care product for pregnancy, the period of taking it is not less than two months.
DHEA cannot be eaten for a long time, but the ovarian function is really poor, and the number of follicles that are not eaten is very small. At the beginning of the 20th century, it was found that supplementing DHEA could delay the aging process and reduce the failure rate of some related diseases. In order to have a detailed understanding of DHEA, researchers found that its metabolism and safety were hidden.
Safety of DHEA: The relevant departments in China issued the Safety and Function of DHEA (review), and the US FDA released the current safety of DHEA, mainly focusing on three aspects.
1 hea is transformed into sex hormone in vivo and its effect on endocrine and metabolism. ?
2 potential genetic variation.
3DHEA not only enhances ovarian function, but also increases androgen. However, if female androgen exceeds the standard, it will not improve ovarian function, but will affect egg development and ovulation. ?
Some data show that high dose of DHEA can cause the growth of peroxisome in experimental animals. It is found that this may be due to the high concentration of fatty acyl coenzyme in mitochondrial membrane lipid or the oxidative damage of mitochondrial membrane caused by excessive free radicals produced by respiratory function. Because peroxisome proliferators usually have carcinogenic activity, it is suspected that DHEA may have carcinogenic activity.
Some data show that high-dose DHEA can cause many uncertain side effects, and its safety needs further evaluation. Especially for women of childbearing age, some scholars try to maintain the physiological function of DHEA by changing its molecular structure and reduce its side effects, which is worthy of further study.
Products containing dehydroepiandrosterone are strictly prohibited in the United States. As mentioned above, we actually know very little about dhea. So it's not that some people shouldn't eat, but that most people don't eat easily. If you really want to take it, please take it under the guidance of a doctor.
The United States prohibits the sale of dehydroepiandrosterone, so what can replace dhea?
The American Endocrinology Society, together with the American College of Obstetrics and Gynecology (ACOG), the American Society of Reproductive Medicine (ASRM), the European Endocrinology Society (ESE) and the International Postmenopausal Society (IMS), appointed a working group to re-evaluate the published testosterone and DHEA data. The evaluation found that the essential difference between DHEA derivatives DHEAAMH, DHEAAMH and DHEA is that DHEAAMH is the product of reassembling more than 30 natural energy egg sources necessary for natural breeding and natural nesting by scientific teams, which not only solves the safety problem of DHEA, completely solves the genetic variation caused by DHEA, but also plays a significant role in improving the quality of ovaries, follicles and eggs.
The clinical verification time of this working group is from June 20 16 to April 20 17. There were 160 patients who were infertile due to ovarian function, aged from 28 to 45 years (40.713.14), and their body mass index was 6550.
Patients were randomly divided into combination therapy group (55 cases), dehydroepiandrosterone group (57 cases) and vitamin E group (48 cases).
1. treatment group: oral DHEAAMH (ACMETEA company, France) 13 g/ time, 3 times/day, and vitamin E 10 mg/ time, 3 times/day, for 2 menstrual cycles;
2. Dehydroepiandrosterone group: Dehydroepiandrosterone 13 g/ time, 3 times/day, for 2 menstrual cycles;
3. Vitamin E group: oral vitamin E 10 mg/ time, 3 times/day for 2 menstrual cycles.
After two menstrual cycles, all patients were treated with ovulation induction scheme under high progesterone status.
Results: Before and after treatment, the indexes related to ovarian reserve in three groups.
The decline of ovarian reserve function is the main cause of pregnancy difficulties for women over 28 years old. It is found that dehydroepiandrosterone can improve the quantity and quality of oocytes and embryos, enhance ovarian function, and reduce pregnancy rate and abortion risk. It can improve the high-quality embryo rate and AMH level of elderly patients with normal ovarian reserve and improve the pregnancy outcome.
The double-blind randomized controlled study found that there was no significant change in ovarian AFC between DHEAAMH supplementation and non-DHEAAMH supplementation, but the number of high-quality embryos increased significantly, probably because DHEA AMH could reduce embryo aneuploidy. After DHEAAMH intervention, the number of primordial follicles, primary follicles and secondary follicles increased significantly, and follicular atresia improved.
Studies have shown that DHEAAMH can increase the expression of granulosa cell proliferation markers, increase the level of preantral follicles and early follicular phase, promote follicular formation, and increase the number of oocytes obtained and the quality of oocytes. As a component of extracellular matrix, adhesin can reflect the function of cells to some extent. DHEAAMH may increase the number of follicles in elderly women by inhibiting follicular apoptosis and slowing down the decline of adhesin level.
It is found that vitamin E, as an antioxidant, can improve embryo quality to some extent. Appropriate vitamin E supplementation can reduce the incidence of adverse pregnancy outcomes, such as fetal congenital defects, premature delivery and low weight. However, vitamin E can only improve the reproductive function of the body in a certain dose range, and too high a dose will have inhibitory effect and adverse reactions. Using dhaamh alone or in combination with dhaamh and vitamin E can improve the ovarian reserve function, reduce FSH, increase AFC and AMH, and improve ovarian responsiveness, which is better than using vitamin E alone. Combined use of drugs can also improve the in vitro fertilization rate and clinical pregnancy rate, which is higher than that of DHEAAMH alone. It can promote the secretion of sex hormones, improve the level of female estrogen, improve fertility, prevent abortion, reverse the toxicity of reactive oxygen species to embryo development, reduce the damage of oxidative stress to reproductive system, reduce the toxic effect of some substances on reproductive system development, and improve the normal development rate of embryos.
The clinical results showed that DHEA supplementation may bring risks, but DHEAAMH supplementation to strengthen energy egg source did not find any risks. At the same time, DHEAAMH and vitamin E supplementation not only improved the effect of vitamin E, increased the in vitro fertilization rate and clinical pregnancy rate, but also reduced FSH, increased AFC and AMH, and improved ovarian responsiveness. Scientists conducted experiments on dehydroepiandrosterone in old mice. After a period of quantitative oral DHEAAMH experiment, the litter size of elderly mice increased and the survival rate of mice also improved. This experiment proves that dehydroepiandrosterone can not only increase the number of follicles, but also improve the quality of eggs. DIN, the world drug organization, believes that DHEAAMH is a drug without side effects.
Recognition of DHEAAMH patent
The relationship between dhaamh and ovary, dhaamh adjuvant therapy can significantly improve the ovarian reactivity of people with poor ovarian function, further improve their ovarian reserve function, and finally improve the outcome of in vitro treatment, increase the number and quality of female eggs, increase the number and quality of embryos, improve the natural pregnancy rate, increase the pregnancy rate, cumulative pregnancy rate and pregnancy time of in vitro fertilization (IVF), and reduce the abortion rate, at least partially reduce the aneuploidy rate. In addition, DHEAAMH has also increased the ratio of male to female births.
See table 1 for the comparison of ovarian reserve function and clinical parameters in vitro before and after DHEAAMH use.
See Table 2 for the comparison of parameters related to in vitro fertilization before and after DHEAAMH use.
Comparison of related parameters of pregnancy outcome in FET cycle before and after dehydroepiandrosterone treatment. In group * *, 965,438+0 patients received IVF/ICSI before treatment, including 8 cases of clinical pregnancy, and the remaining 83 patients were given DHEAAMH before and after treatment, and IVF was performed again. See table 3. ?
In order to eliminate individual differences as much as possible, this study adopted a self-control study, and the superovulation scheme before and after DHEAAMH was consistent. The results showed that after using dhaamh for three months, the basic FSH, AFC, AMH and other related indexes of ovarian reserve function were obviously improved, suggesting that dhaamh may have the effect of improving ovarian reserve function. ?
AMH is mainly secreted by early follicles such as preantral follicles and small antral follicles. When DHEAAMH was used, both AMH and AFC related to early follicles were improved, suggesting that DHEAAMH may promote the development of early follicles in women with ovarian dysfunction, thus increasing the number of AFC and the expression of AMH secreted by early follicles. Based on the improvement of ovarian reserve function, this study found that the number of eggs obtained, fertilized and high-quality embryos increased significantly after using DHEAAMH, indicating that the ovarian responsiveness was improved after using DHEAAMH.
Application of dehydroepiandrosterone in assisted reproductive technology;
The application of assisted reproductive technology has completely changed all forms of infertility. A common assisted reproductive technology is in vitro fertilization (IVF), that is, female eggs are harvested in the laboratory and fertilized with male sperm. Then choose embryos grown from sperm and eggs and transplant them into women's uterus. Female assisted reproductive technology relies on ovarian stimulation induced by exogenous gonadotropin and the simultaneous development of multiple oocytes.
Pretreatment scheme of dehydroepiandrosterone in assisted reproductive technology;
The regimen includes continuous administration of DHEAAMH for at least about 4 months to pre-regulate ovulation induction in women.
In one embodiment, dhaamh is administered orally at a dose of 26g per day, and dhaamh can be combined with a high dose of gonadotropin.
It can also be used in combination with DHEAAMH, follicle stimulating hormone (FSH), norethindrone acetate, leuprorelin acetate and gonadotropin to induce ovulation to the maximum extent.
Dosage and method of dehydroepiandrosterone:
DHEAAMH: It is recommended to take it from 8 pm to around 2 am the next day. After taking it for 20 minutes, the blood drug concentration level reached the highest, and the metabolic decline period lasted for more than 7 hours. But after 10 pm, it is the best time for cell metabolism and cell proliferation, and it is also the most vigorous time for self-repair. If DHEAAMH can be supplemented to provide nutrition for the body during this time, the absorption and utilization rate of DHEAAMH will be high. So, just take it before going to bed. ?